Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02848326 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 834
- Enrollment target
NCT02848326 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 834 participants.
The verdict
NCT02848326, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 834 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.
Interventions
- DRUG Atogepant
- DRUG Placebo-matching Atogepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 834 participants |
| Start Date | 2016-09-06 |
| Est. Completion | 2018-04-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02848326
The ClinicalTrials.gov registry entry for NCT02848326 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 834 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atogepant is the first listed.
NCT02848326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02848326 about?
NCT02848326 is a clinical study titled "Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention". This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.
What is the current status of trial NCT02848326?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 834 participants. The study started on 2016-09-06. Estimated completion is 2018-04-23.
What interventions are being tested in trial NCT02848326?
The interventions under investigation include: Atogepant (DRUG), Placebo-matching Atogepant (DRUG).
Who is sponsoring clinical trial NCT02848326?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.